Foveal LLP Independent Investment Research Foveal Research

We examine in detail, the prospects of five near term Pfizer pipeline assets, slated for the FDA over the next 3 years and find that there a

The first factor XIa clinical efficacy for stroke prevention was presented at the European Society of cardiology in Barcelona yesterday...

We undertake a detailed analysis of seven near term Roche pipeline assets, spanning Roche’s market leading positions in Non-Hodgkin...

We present an update on the state of the factor XI competitive market, building upon our previous analysis of three factor XI inhibitors for

Bristol's announcement that it is not pursuing an accelerated FDA approval pathway for Yervoy and Opdivo in first line lung cancer was...

Head and neck specific? The FDA placed a partial clinical trial hold on recruiting new patients to AstraZeneca’s anti PD-L1 (durvalumab)...

Chemo combos continue to look equivocal, while IO combos remain durable as MYSTIC’s shadow clears New ESMO lung cancer data bodes well...

Astra's underappreciated oncology pipeline stalking the market We initiate on AstraZeneca with an overweight rating and a Target Price of...

Pressure on anti PD-L1s: ESMO 2016 increases the body of evidence that anti PD-L1s from Roche, Astra and PFE/MRCG may fall short of PD-1s...

PD1 market continues to shrink, but Bristol’s failure not good news for rivals BMY announced Friday that its pivotal phase III study of...